SC
ORMP icon

Steven Cohen’s Oramed Pharmaceuticals ORMP Stock Holding History

Steven Cohen’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,052
Closed -$88.6K – 4441
2026
Q1 		$88.6K Buy
26,052
+610
+2% +$2.07K ﹤0.01% 3624
2025
Q4 		$72.5K Buy
+25,442
New +$65.6K ﹤0.01% 3764

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steven Cohen's ORMP Position: Q2 2026 in Review

Steven Cohen sold out of Oramed Pharmaceuticals (ORMP) in Q2 2026, closing a stake of 26,052 shares — an estimated $88.6K sold.

Steven Cohen first reported a position in ORMP in Q4 2025 and held it in 2 quarters. The position peaked at $88.6K in Q1 2026. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Steven Cohen reported no remaining Oramed Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 26,052 Oramed Pharmaceuticals shares in Q2 2026, an estimated $88.6K.
  • Steven Cohen first reported a position in Oramed Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Steven Cohen's Oramed Pharmaceuticals position peaked at $88.6K in Q1 2026.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.